Pfizer/BioNTech, Moderna Vaccines Take Baby Steps Into Booster Shots

Moderna may benefit from data indicating strong efficacy against the Delta strain, though an analyst pointed out that they come with some important caveats.

Adolescent covid vaccination US
The FDA expanded the EUAs for Pfizer/BioNTech and Moderna's COVID-19 vaccines to include third shots for severely immunocompromised individuals • Source: Shutterstock

While the commercial position of Pfizer Inc./BioNTech SE’s and Moderna, Inc.’s COVID-19 vaccines would strengthen if it is recommended that people who received the initial two-dose vaccination series of BNT162b2 or mRNA-1273 get boosters, the US Food and Drug Administration’s expansion of the vaccines’ emergency use authorizations to include third shots for certain vulnerable people accounts for only a very small number of patients. But as variants of concern continue spreading, Moderna may have an upper hand, with data showing strong efficacy against the Delta strain, though those results come with certain caveats.

The FDA said late on 12 August that it amended the EUAs for the two vaccines to allow for additional...

More from COVID-19

More from Scrip

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.